Short Interest in Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Rises By 230.8%

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the recipient of a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 8,600 shares, a growth of 230.8% from the December 31st total of 2,600 shares. Based on an average daily volume of 362,400 shares, the short-interest ratio is currently 0.0 days.

Oncotelic Therapeutics Trading Up 2.9 %

Shares of Oncotelic Therapeutics stock traded up $0.00 on Wednesday, hitting $0.03. The stock had a trading volume of 1,500 shares, compared to its average volume of 181,029. The company has a quick ratio of 0.01, a current ratio of 0.01 and a debt-to-equity ratio of 0.28. Oncotelic Therapeutics has a one year low of $0.02 and a one year high of $0.05. The stock has a market cap of $11.38 million, a price-to-earnings ratio of -2.80 and a beta of -0.27. The stock’s 50-day simple moving average is $0.03 and its two-hundred day simple moving average is $0.03.

Oncotelic Therapeutics Company Profile

Oncotelic Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.